Axogen, Inc.

Listed Company

AXGNCIK 0000805928NasdaqAcceleratedElectromedical & Electrotherapeutic ApparatusMinnesotaFY ends Dec 31

Period

FY 2025

Revenue

$225.21M

Net Income

$-15.70M

Total Assets

$221.69M

Equity

$128.85M

Shares Out

53.18M

Op. Cash Flow

$812.0K

AXGN$39.83+242.48% · past yearDBEQ Basic

Daily closing prices

Business

Axogen is a regenerative medicine company focused on peripheral nerve repair and regeneration. It provides a comprehensive portfolio of surgical repair products including Avance Nerve Graft (an acellular nerve allograft recently approved by the FDA as a biologic), Axoguard Nerve Connector and Protector (porcine extracellular matrix products), and Avive+ Soft Tissue Matrix. The company serves surgeons in trauma, oral maxillofacial, breast reconstruction, and urology through direct sales in the U.S. and international distributors in Canada, Germany, the U.K., Spain, and other countries.

Summary from 10-K filed 2026-02-24

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenues	225	187	159	139	127
Cost of goods sold	58	45	37	30	23
Gross profit	167	142	122	109	104
Sales and marketing	98	78	78	72	73
Research and development	33	28	27	26	24
General and administrative	45	39	38	41	32
Total costs and expenses	175	145	143	139	130
Loss from operations	−8	−3	−21	−30	−25
Investment income	1	1	1	569,000	93,000
Interest expense	−8	−8	−3	−624,000	—
Change in fair value of debt derivative liabilities	−1	587,000	2	1	−28,000
Other income (expense), net	167,000	−199,000	−437,000	−230,000	−278,000
Total other expense, net	−8	−7	−254,000	759,000	−2
Net loss	−16	−10	−22	−29	−27
Weighted average common shares outstanding - basic (in shares)	46	44	43	42	41
Weighted average common shares outstanding - diluted (in shares)	46	44	43	42	41
Net loss per common share - basic (in USD per share)	−0.34	−0.23	−0.51	−0.69	−0.65
Net loss per common share - diluted (in USD per share)	−0.34	−0.23	−0.51	−0.69	−0.65

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	36	28	31	15	33
Restricted cash	4	6	6	6	6
Investments	6	6	0	34	51
Accounts receivable, net of allowance for doubtful accounts of $948 and $788, respectively	26	24	25	22	18
Inventory	42	33	23	19	17
Prepaid expenses and other assets	6	2	3	2	2
Total current assets	120	99	88	98	127
Property and equipment, net	82	85	89	79	63
Operating lease right-of-use assets	13	14	16	14	15
Intangible assets, net	7	6	5	4	3
Total assets	222	204	197	195	208
Accounts payable and accrued expenses	21	29	29	22	22
Current maturities of long-term lease obligations	2	2	2	1	2
Total current liabilities	24	31	30	24	24
Long-term debt, net of debt discount and financing fees	48	47	47	46	45
Long-term lease obligations	17	19	21	20	21
Debt derivative liabilities	4	2	3	5	6
Other long-term liabilities	141,000	94,000	0	—	0
Total liabilities	93	100	101	94	95
Commitments and contingencies - see Note 15	—	—	—	—	—
Common stock, $0.01 par value per share; 100,000,000 shares authorized; 47,199,797 and 44,148,836 shares issued and outstanding	472,000	441,000	431,000	424,000	417,000
Additional paid-in capital	435	395	377	360	343
Accumulated deficit	−307	−291	−281	−260	−231
Total shareholders equity	129	104	96	101	113
Total liabilities and shareholders equity	222	204	197	195	208

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation	7	6	4	3	3
Amortization of right-of-use assets	2	1	1	2	—
Amortization of intangible assets	315,000	267,000	273,000	265,000	202,000
Amortization of debt discount and deferred financing fees	891,000	893,000	891,000	891,000	831,000
Loss on disposal of equipment	0	0	56,000	0	0
Provision for (recovery of) bad debts	400,000	650,000	−271,000	612,000	−41,000
Investment gains, net	−329,000	−155,000	−666,000	−228,000	68,000
Impairment of long-lived assets	64,000	0	0	—	—
Stock-based compensation expense	30	16	14	16	11
Accounts receivable	−2	392,000	−3	−5	−499,000
Inventory	−9	−10	−4	−2	−7
Prepaid expenses and other assets	−4	784,000	−867,000	−84,000	2
Accounts payable and accrued expenses	−7	125,000	7	660,000	−270,000
Operating lease obligations	−2	−2	−1	−2	−463,000
Cash paid for interest portion of financing lease obligations	−11,000	−4,000	−3,000	−2,000	−2,000
Other long-term liabilities	47,000	424,000	−14,000	—	—
Net cash provided by (used in) operating activities	812,000	5	−6	−16	−13
Purchase of property and equipment	−4	−3	−14	−20	−28
Purchase of investments	−14	−6	−10	−39	−69
Proceeds from sale of investments	14	0	44	57	73
Cash payments for intangible assets	−2	−1	−1	−1	−589,000
Net cash (used in) provided by investing activities	−5	−10	19	−3	−24
Cash paid for debt portion of financing lease obligations	−32,000	−10,000	−10,000	−12,000	−15,000
Proceeds from exercise of stock options and ESPP stock purchases	11	2	2	2	5
Net cash provided by financing activities	10	2	2	2	20
Net increase (decrease) in cash and cash equivalents, and restricted cash	6	−3	15	−17	−17
Cash paid for interest, net of capitalized interest	7	7	2	0	495,000
Acquisition of property and equipment change in accounts payable and accrued expenses	−1,000	114,000	704,000	—	—
Obtaining a right-of-use asset in exchange for a lease liability	31,000	21,000	2	1	1
Acquisition of intangible assets change in accounts payable and accrued expenses	−298,000	299,000	407,000	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Axogen, Inc.'s CIK number?

Axogen, Inc.'s SEC CIK number is 0000805928 (805928). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Axogen, Inc.'s SEC filings?

All of Axogen, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Axogen, Inc. last report earnings?

Axogen, Inc. (AXGN) most recently filed an earnings 8-K with the SEC on Apr 28, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0000805928-26-000051). This is Axogen, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is Axogen, Inc.'s most recent earnings 8-K?

Axogen, Inc.'s latest earnings 8-K (Item 2.02) was filed Apr 28, 2026 under accession 0000805928-26-000051. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Axogen, Inc.'s latest earnings 8-K →
Look up any company's CIK number →